ArticlePloS one2025
Numerical study on the supersonic gas-solid two-phase injection mechanism of needle-free syringe.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Supersonic gas-solid injection technology finds extensive use in drug particle delivery systems. However, the combined impact of particle diameter and mass flow rate on the delivery efficiency remain insufficiently explored. Within the Euler-Lagrange framework, this study utilizes the discrete phase method (DPM) for the numerical simulation of supersonic gas-particle flow in a needle-free injector. After validating the model's accuracy with experiment results, further investigations were conducted into the influences of particle size and mass flow rate on particle behavior and flow field properties. The results indicate that the impact of larger particles on the compressible structure is stronger, while higher mass flow rate absorbs greater energy from the gas phase, reducing the gas expansion capacity, which results in lower velocity, Mach number, and higher temperature. The jet core zone is approximately x/X = 0.3 in length. Outside core zone, the gas velocity rapidly decays and temperature rises sharply. Within the jet core zone, drug particles are accelerated and cooled, while beyond core zone, they decelerate and heat up. The strongest inter-phase interactions occur primarily in the nozzle expansion area and the jet core zone. Smaller particles reach maximum velocity upstream. This implies that in designing needle-free injectors, the nozzle-to-skin distance must match the drug particle diameter to achieve maximum penetration effectiveness. Furthermore, the particle temperature decreases with smaller sizes. As the particle diameter rises from 10 μm to 100 μm, the minimum temperatures of the particles are 145 K and 264 K, respectively, indicating the need to match the particle diameter with the minimum temperature at which the drug particles remain effective. Additionally, higher mass flow rate doses reduce injection velocity and penetration ability, necessitating the rational control of the administered dose range. These results offer significant theoretical guidance for the design and improvement of needle-free injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.